Q32 Bio (QTTB) Convertible Debt (2023)
Q32 Bio's (QTTB) quarterly Convertible Debt came in at $38.6 million in Q4 2023.
Q32 Bio (QTTB) Convertible Debt (2023) Analysis & Trends
Q32 Bio's Convertible Debt history runs 1 years deep, the most recent figure standing at $38.6 million for Q4 2023.
- On a quarterly basis, Convertible Debt changed N/A year-over-year to $38.6 million in Q4 2023; TTM through Dec 2023 was $38.6 million, a N/A change from a year earlier, with the FY2023 full-year figure at $38.6 million, changed N/A from the prior year.
- Convertible Debt was little changed at $38.6 million in Q4 2023 per QTTB's latest filing.
- Across five years, Convertible Debt topped out at $38.6 million in Q4 2023 and bottomed at $38.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Q32 Bio | 215.66 Mn | 164.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 38.60 Mn |